The phrase "GxP-ready" gets used a lot in life sciences IT. It's on vendor websites, in investor due diligence questions, and in job descriptions for QA engineers. But what does GxP-ready IT actually look like for a 20-person biotech that just closed its Series A and is running its first GLP studies?
This post gives you a concrete answer — the foundational systems, documentation, and processes you need in place before your first FDA audit, without overcapitalizing on enterprise infrastructure you won't need for three years.
What GxP Means (and Which "x" Applies to You)
GxP is the umbrella term for a family of "Good Practice" regulations. The relevant ones for most early-stage biotechs:
- GLP (Good Laboratory Practice, 21 CFR Part 58): Governs non-clinical safety studies submitted to FDA. If you're running toxicology or pharmacokinetic studies in your own facility or at a CRO, GLP applies.
- GCP (Good Clinical Practice, 21 CFR Part 312): Governs the conduct of clinical trials involving human subjects. Applies from your first IND onward.
- GMP (Good Manufacturing Practice, 21 CFR Part 211 for drugs, 21 CFR Part 820 for devices): Governs manufacturing. Applies when you're making drug product for clinical trials or commercial use.
Each of these has its own documentation requirements, and 21 CFR Part 11 overlaps with all of them — applying to any electronic record created under any GxP requirement.
The Four Non-Negotiables
1. A Documented System Inventory
Before you can validate your systems, you need to know what they are. A system inventory (sometimes called a system register) lists every software system used in regulated activities, classifies each system by its GxP impact (high, medium, low), and records its validation status. This document is often the first thing an FDA inspector asks to see. If you don't have one, that's your starting point.
2. Validated Electronic Records Systems
Whatever systems you use to create or maintain regulated records — your ELN, LIMS, QMS, eTMF — must be validated. That means IQ/OQ/PQ documentation, written protocols, executed test scripts, and deviation records. Validation doesn't need to be elaborate for low-risk systems, but it needs to exist and be current. "We use [Vendor X] and they're Part 11 compliant" is not validation.
3. Access Control and Audit Trail Verification
Every regulated system needs: unique user accounts (no sharing), role-based access limited to job function, and enabled audit trails. Critically, audit trails need to be periodically reviewed — not just enabled. FDA inspectors ask to see evidence of audit trail review, and "we have it enabled" without review records is a finding.
4. Backup and Recovery with Tested Restores
Regulated data must be backed up, and the backups must be tested. "We have automated backup" is insufficient without evidence of periodic restore tests. Document your RTO (recovery time objective) and RPO (recovery point objective) in your business continuity plan, and execute restore tests at least quarterly. Document every test, including any failures and their resolutions.
What You Don't Need Yet
GxP-ready IT for an early-stage company doesn't mean implementing a full enterprise quality management system, a validated MES, or a clinical data management system before you have clinical data. The temptation to over-engineer early is real — especially when your quality team is worried about audits — but it diverts resources and creates validation burden you're not ready to sustain.
A proportionate approach: validate the systems you're using now, document clearly, and build in the headroom to scale your compliance infrastructure as your pipeline advances.
The Audit Readiness Mindset
The biggest shift early-stage biotechs need to make is from "preparing for audits" to "always audit-ready." An FDA inspection can be announced with two days notice, or less. If your compliance documentation is current only when you're expecting a visit, you will eventually be caught off-guard.
Build systems where maintaining compliance documentation is the path of least resistance, not an additional burden. Change control that's automatic, validation documentation that updates when software does, audit trail reviews that happen on a calendar rather than ad hoc. That's what GxP-ready IT looks like in practice.
Where to Start
If you're starting from scratch, do a regulatory system mapping first: list every system you use in regulated activities and assess the current state of each. That gap assessment tells you exactly what to prioritize. Most early-stage companies have two or three high-priority gaps that, once closed, get them to a defensible baseline.
For a deeper dive into specific requirements, see our IND-ready IT pillar guide or explore our Life Sciences IT services.
This article is part of Propellio's series on IT for life sciences and biotech. See related: Life Sciences It.
← Back to all posts